Premium
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment
Author(s) -
Yin Jie,
Tian Hong,
Kong Danqing,
Li Yun,
Gu Chengyuan,
Wang Zhaoyue,
Wu Depei,
Yu Ziqiang
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18430
Subject(s) - rituximab , bortezomib , medicine , thrombotic thrombocytopenic purpura , refractory (planetary science) , lenalidomide , hematology , oncology , platelet , dermatology , multiple myeloma , lymphoma , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom